Medication Description: Medroxyprogesterone acetate (Medroxyprogesterone acetate)

MEDROXYPROGESTERONE ACETATE (Medroxyprogesterone acetate). 17-Hydroxy-6α-methylpregn-4-en-3, 20-dione acetate.

Synonyms: Depo-Provera, Provera, Farlutal, Clinovir, Depcorlutin, Depo-Alphacort, Depo-Clinovie, Depo-Promone, Depo-Provera, Farlutal, Farmolut, Gestopuran, Luteodione, Metilgestene, Neolut, Nidaxin, Normobion, Onco-Provera, Prodafem, Promone-E, Provera, Proverone, Sedometril, Vadecin and others.

By chemical structure is close to the derivatives of progesterone (see) for the main mode of action is progestin (gestagen). As a gestagenic agent has application in menstrual disorders, dysfunctional uterine bleeding. However, the main use of the drug found as an antitumor agent in hormone-sensitive malignant tumors (see Progesterone capronate), especially in breast cancer and uterine cancer (endometrium). The effect is associated not only with gestagenic, but also with anti-estrogenic, antiandrogenic and antiagonantotropic activity.

In breast cancer, there was a correlation between the efficacy of medroxyprogesterone and the concentration of estrogen and progesterone receptors in tumor tissue.

The drug can be used in the form of monotherapy or in combination with anti-estrogens (see) or cytostatics.

Medroxyprogesterone acetate is used mainly as an anticancer agent for additional and (or) palliative therapy of relapses and / or metastasis of endometrial and renal cancer, as well as for the treatment of relapses of hormone-dependent breast cancer in postmenopausal women.

The drug is used orally or intramuscularly.

Medroxyprogesterone provera is available in two forms: a) Provera tablets and b) Depo-provera suspension.

Prover tablets are prescribed inside for endometrial cancer and kidneys from 200 to 600 mg per day, for breast cancer - from 400 to 1200 mg per day. The effect is usually observed after 8 to 10 weeks from the start of treatment.

Depo-provera is injected intramuscularly in the form of a suspension (150 mg of the drug in 1 ml) with endometrial and kidney cancer 400-1000 mg once a week. When the condition is improved, the dose is reduced to 400 mg and administered once a month.

In breast cancer, 500 mg daily for 28 days, then 500 mg 2 times a week until the effect is maintained.

When the disease progresses, medroxyprogesterone therapy with acetate is discontinued (as with other similar drugs).

Possible side effects and contraindications are basically the same as when using other progestogens.

When using the suspension, seals and sterile abscesses at the site of administration are possible.

Form release: tablets of 100; 200; 250; 400 mg (0.1, 0.2, 0.25, 0.4 g); Suspension for oral administration, containing 500 mg in 1 ml: suspension for intramuscular injection (depo-probe) in vials of 3, 3 ml (500 mg or 150 mg in 1 ml) and 6, 7 ml (1000 mg).